A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931 (vol 9, 1355, 2018)

Ozkaynak M Fevzi<sup>*</sup>; Gilman Andrew L; London Wendy B; Naranjo Arlene; Diccianni Mitchell B; Tenney Sheena C; Smith Malcolm; Messer Karen S; Seeger Robert; Reynolds C Patrick; Smith L Mary; Shulkin Barry L; Parisi Marguerite; Maris John M; Park Julie R; Sondel Paul M; Yu Alice L<sup>*</sup>

doi:10.3389/fimmu.2018.01641

免费注册

赞收藏引用

科研之友

微信

新浪微博

Facebook

分享链接

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931 (vol 9, 1355, 2018)

作者：Ozkaynak M Fevzi^*; Gilman Andrew L; London Wendy B; Naranjo Arlene; Diccianni Mitchell B; Tenney Sheena C; Smith Malcolm; Messer Karen S; Seeger Robert; Reynolds C Patrick; Smith L Mary; Shulkin Barry L; Parisi Marguerite; Maris John M; Park Julie R; Sondel Paul M; Yu Alice L^*

来源：Frontiers in Immunology, 2018, 9: 1641.

DOI：10.3389/fimmu.2018.01641